{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:47:00Z","timestamp":1793249220970,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"\n Importance<\/jats:title>\n Obesity is a worldwide problem and a major public health issue in China.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of \u226530).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabetes that was conducted at 27 hospitals from December 2023 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized in a 2:1 ratio to receive a once weekly, 9-mg dose of mazdutide administered subcutaneously (n\u2009=\u2009308) or placebo (n\u2009=\u2009154) as an adjunct to a reduced calorie diet and increased physical activity for 60 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The coprimary outcomes were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 60. The efficacy and safety analyses were performed in participants who received at least 1 dose of the study treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 461 participants (295 [64.0%] female; 16.1% with type 2 diabetes; mean age, 33.9 [SD, 8.4] years; body weight, 94.0 [SD, 13.8] kg; BMI, 34.3 [SD, 3.2]) received the study treatment (307 in the mazdutide group and 154 in the placebo group) and were included in the analyses. At week 60, the mean percentage change in body weight from baseline was \u201316.65% (95% CI, \u201318.19% to \u201315.12%) in the mazdutide group compared with \u20131.50% (95% CI, \u20133.43% to 0.43%) in the placebo group (between-group difference, \u221215.15% [95% CI, \u221217.22% to \u221213.09%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). At week 60, 84.3% of participants in the mazdutide group had a body weight reduction of 5% or greater compared with 33.1% in the placebo group (between-group difference, 51.6% [95% CI, 43.0% to 60.1%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Adverse events leading to study treatment discontinuation were reported in 2.9% of participants in the mazdutide group compared with 0% in the placebo group. The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%); most of the adverse events were mild to moderate in severity.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Mazdutide provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06164873<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.8142","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:30:17Z","timestamp":1780839017000},"page":"377","source":"Crossref","is-referenced-by-count":9,"title":["Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity"],"prefix":"10.1001","volume":"336","author":[{"given":"Leili","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital and College of Clinical Medicine, State Key Laboratory of Light Superalloys, Henan University of Science and Technology, Luoyang, China"},{"name":"State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Second Norman Bethune Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhang","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Luoyang Third People\u2019s Hospital, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huzhou Central Hospital, Huzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, People\u2019s Hospital of Xuancheng, Xuancheng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, China National Petroleum Corporation Central Hospital, Langfang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jinan Central Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suzhou Municipal Hospital, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiang","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Ma","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Deng","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han-Zhang","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Innovent Biologics Inc, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GLORY-2 Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufang","family":"Lian","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchun","family":"Lv","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Meng","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"He","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Lu","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqin","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihu","family":"Qin","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the GLORY-2 Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"joi260050r1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China.","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10481","key":"joi260050r2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"joi260050r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102309","article-title":"Revisiting obesity thresholds for cardiovascular disease and mortality risk in Chinese adults: age- and gender-specific insights.","volume":"6","author":"Jia","year":"2025","journal-title":"Cell Rep Med"},{"issue":"11","key":"joi260050r4","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/dom.15238","article-title":"Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults.","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"joi260050r5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(21)00047-4","article-title":"Clinical management and treatment of obesity in China.","volume":"9","author":"Zeng","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"joi260050r6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S2213-8587(25)00357-2","article-title":"Obesity in China: current progress and future prospects.","volume":"14","author":"Pan","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"joi260050r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2025.171393","article-title":"Oxyntomodulin\u2014past, present and future.","volume":"188","author":"Holst","year":"2025","journal-title":"Peptides"},{"issue":"8108","key":"joi260050r8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-025-10031-z","article-title":"Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.","volume":"652","author":"Guo","year":"2026","journal-title":"Nature"},{"issue":"8108","key":"joi260050r9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-025-10026-w","article-title":"Mazdutide versus placebo in Chinese adults with type 2 diabetes.","volume":"652","author":"Zhu","year":"2026","journal-title":"Nature"},{"issue":"22","key":"joi260050r10","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight.","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260050r11","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"joi260050r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101063","article-title":"Mazdutide 9 mg in Chinese adults with a body mass index =30 kg\/m2 but without diabetes: a phase 2 randomized controlled trial.","volume":"7","author":"Ji","year":"2026","journal-title":"Med"},{"issue":"10294","key":"joi260050r13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(21)00798-4","article-title":"Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.","volume":"398","author":"Wang","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"joi260050r14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years.","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"joi260050r15","doi-asserted-by":"publisher","first-page":"e1005","DOI":"10.1016\/S2468-2667(24)00043-4","article-title":"Early adulthood BMI and cardiovascular disease: a prospective cohort study from the China Kadoorie Biobank.","volume":"9","author":"Chen","year":"2024","journal-title":"Lancet Public Health"},{"issue":"7","key":"joi260050r16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial.","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"joi260050r17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"joi260050r18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ndt\/gfaf110","article-title":"GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.","volume":"41","author":"Apperloo","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"joi260050r20","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"joi260050r21","doi-asserted-by":"publisher","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"joi260050r22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2-4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"joi260050r19","unstructured":"China Center for Drug Evaluation; China National Medical Products Administration. Technical guidelines for clinical trials of weight control drugs. Accessed May 19, 2026. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/75001677bbb075c037afff20e96461d1"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2850143\/jama_gao_2026_oi_260050_1784833437.61835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:00:37Z","timestamp":1785855637000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2850143"}},"subtitle":["The GLORY-2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.8142","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}